What smart money is saying about Teva Pharmaceutical Industries Limited
TEVA
No fund has written a full thesis on Teva Pharmaceutical Industries Limited in our archive, but 1 fund letter reports a position in it — most recently Baron Health Care Fund in June 2026.
1
Reported positions
0
Bought
0
Sold
3
Letters
Position history
Every position in Teva Pharmaceutical Industries Limited on record in the archive was reported in Q2 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 0 |
Fund activity · 1 position
- June 2026
Listed in Baron Health Care Fund’s reported holdings.
Read the letterTeva Pharmaceutical Industries Limited
Also mentioned · 2
These funds discuss Teva Pharmaceutical Industries Limited — as a competitor, benchmark or comparable — without disclosing a position in it.
- June 2026
“Major players like Teva and Sandoz have rationalized their portfolios to exit traditional oral solids and shifted their capacity towards more complex deliveries, like inhalers and injectables.”
Read the letterTeva Pharmaceutical Industries Limited - MentionedThird Avenue Small-Cap Value FundMarch 2026
“Catalyst has prevailed multiple times in defending its intellectual property against three other generic manufacturers including Teva Pharmaceuticals, Inventia Healthcare and Lupin Pharmaceuticals, while the U.S. Court of Appeals for the 11th Circuit has ruled in favor of Catalyst intellectual property rights.”
Read the letterTeva Pharmaceutical Industries Limited
Read the letters behind these Teva Pharmaceutical Industries Limited positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger